Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Roger

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Headache|July 31, 2003
Botulinum toxin type A: myths, facts, and current researchStephen D Silberstein, K Roger Aoki
Journal of Biomechanics|May 30, 2008
Re: Botox produces functional weakness in non-injected muscles adjacent to the target muscleK Roger Aoki, Ryan Irvine, Conor Gallagher
Immunobiology|August 25, 2014
Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxinMinako Oshima, K Roger Aoki, M Zouhair Atassi
Langmuir : the ACS Journal of Surfaces and Colloids|October 16, 2019
Emulsions Stabilized by Gum Arabic: How Diversity and Interfacial Networking Lead to MetastabilityM Atgié, Alexis Chennevière, O Masbernat, et al.
Critical Reviews in Immunology|April 8, 2010
Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognitionK Roger Aoki, Leonard A Smith, M Zouhair Atassi
Psychological Reports|September 25, 2007
Concurrent validity of the WISC-IV in eligibility decisions for students with educable mental disabilitiesKathryn B Launey, James Carroll, K Roger Van Horn
Immunology Letters|February 18, 2011
Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugatesBehzod Z Dolimbek, K Roger Aoki, M Zouhair Atassi
Infection and Immunity|January 28, 2015
The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactionsB Vijayalakshmi Ayyar, K Roger Aoki, M Zouhair Atassi
The Journal of Pharmacology and Experimental Therapeutics|June 26, 2010
Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibersGary W Lawrence, K Roger Aoki, J Oliver Dolly
Gene|October 15, 2003
Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strainLi Zhang, Wei-Jen Lin, Shengwen Li, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Headache|July 31, 2003
Botulinum toxin type A: myths, facts, and current researchStephen D Silberstein, K Roger Aoki
Journal of Biomechanics|May 30, 2008
Re: Botox produces functional weakness in non-injected muscles adjacent to the target muscleK Roger Aoki, Ryan Irvine, Conor Gallagher
Immunobiology|August 25, 2014
Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxinMinako Oshima, K Roger Aoki, M Zouhair Atassi
Langmuir : the ACS Journal of Surfaces and Colloids|October 16, 2019
Emulsions Stabilized by Gum Arabic: How Diversity and Interfacial Networking Lead to MetastabilityM Atgié, Alexis Chennevière, O Masbernat, et al.
Critical Reviews in Immunology|April 8, 2010
Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognitionK Roger Aoki, Leonard A Smith, M Zouhair Atassi
Psychological Reports|September 25, 2007
Concurrent validity of the WISC-IV in eligibility decisions for students with educable mental disabilitiesKathryn B Launey, James Carroll, K Roger Van Horn
Immunology Letters|February 18, 2011
Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugatesBehzod Z Dolimbek, K Roger Aoki, M Zouhair Atassi
Infection and Immunity|January 28, 2015
The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactionsB Vijayalakshmi Ayyar, K Roger Aoki, M Zouhair Atassi
The Journal of Pharmacology and Experimental Therapeutics|June 26, 2010
Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibersGary W Lawrence, K Roger Aoki, J Oliver Dolly
Gene|October 15, 2003
Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strainLi Zhang, Wei-Jen Lin, Shengwen Li, et al.
Pageof 8